Portal Hypertension As Immune Mediate Disease

Overview

Journal Hepat Mon

Publisher Brieflands

Specialty Gastroenterology

Date 2014 Jul 1

PMID 24976841

Citations 4

Authors

Sara Manti

Lucia Marseglia

Gabriella DAngelo

Martina Filippelli

Caterina Cuppari

Eloisa Gitto

Claudio Romano

Teresa Arrigo

Carmelo Salpietro

Affiliations

Soon will be listed here.

Abstract

Context: Portal Hypertension (PH) is a progressive complication due to chronic liver disease. In addition to pathophysiologic changes in the micro-circulation, in PH are established fibrous tissue (periportal fibrous septal) and regenerative hyperplastic nodules (from micro- to macro-nodules) promoting hepatic architectural distortion.

Evidence Acquisition: A literature search of electronic databases was undertaken for the major studies published from 1981 to today. The databases searched were: PubMed, EMBASE, Orphanet, Midline and Cochrane Library. We used the keywords: "portal hypertension, children, immune system, endocrine system, liver fibrosis".

Results: It is believed that PH results from three "phenotype": ischemia-reperfusion, involving nervous system (NS); edema and oxidative damage, involving immune system; inflammation and angiogenesis, involving endocrine system. However, its exact cause still underdiagnosed and unknown.

Conclusions: PH is a dynamic and potentially reversible process. Researchers have tried to demonstrate mechanisms underlying PH and its related-complications. This review focuses on the current knowledge regarding the pathogenesis, and immune, endocrine-metabolic factors of disease. The strong positive association between immune system and development of PH could be efficient to identify non-invasive markers of disease, to modify prognosis of PH, and to development and application of specific and individual anti-inflammatory therapy.

Citing Articles

Nonresponse to intramuscular vaccination: An unmet need in hepatitis B vaccination.

Manti S, Parisi G, Leonardi S Saudi J Gastroenterol. 2020; .

PMID: 33078721 PMC: 8019139. DOI: 10.4103/sjg.SJG_472_20.

The role of inhalational anesthetic drugs in patients with hepatic dysfunction: a review article.

Soleimanpour H, Safari S, Rahmani F, Ameli H, Alavian S Anesth Pain Med. 2015; 5(1):e23409.

PMID: 25789242 PMC: 4350156. DOI: 10.5812/aapm.23409.

Role of the diet as a link between oxidative stress and liver diseases.

Arrigo T, Leonardi S, Cuppari C, Manti S, Lanzafame A, DAngelo G World J Gastroenterol. 2015; 21(2):384-95.

PMID: 25593454 PMC: 4292270. DOI: 10.3748/wjg.v21.i2.384.

Oxidative stress in obesity: a critical component in human diseases.

Marseglia L, Manti S, DAngelo G, Nicotera A, Parisi E, Di Rosa G Int J Mol Sci. 2014; 16(1):378-400.

PMID: 25548896 PMC: 4307252. DOI: 10.3390/ijms16010378.

References

Tazi K, Moreau R, Herve P, Dauvergne A, Cazals-Hatem D, Bert F . Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology. 2005; 129(1):303-14. DOI: 10.1053/j.gastro.2005.04.016. View

Steib C, Bilzer M, Op den Winkel M, Pfeiler S, Hartmann A, Hennenberg M . Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. Hepatology. 2010; 51(6):2086-96. DOI: 10.1002/hep.23596. View

Ziol M, Poirel H, Kountchou G, Boyer O, Mohand D, Mouthon L . Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. Hum Pathol. 2004; 35(10):1241-51. DOI: 10.1016/j.humpath.2004.06.016. View

Eslam M, Ampuero J, Jover M, Abd-Elhalim H, Rincon D, Shatat M . Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. Ann Hepatol. 2013; 12(4):588-98. View

Iwakiri Y, Tsai M, McCabe T, Gratton J, Fulton D, Groszmann R . Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol. 2002; 282(6):H2084-90. DOI: 10.1152/ajpheart.00675.2001. View

Xia Z, Wang G, Wan C, Liu T, Wang S, Wang B . Expression of NALP3 in the spleen of mice with portal hypertension. J Huazhong Univ Sci Technolog Med Sci. 2010; 30(2):170-2. DOI: 10.1007/s11596-010-0207-0. View

Vorobioff J, Bredfeldt J, Groszmann R . Increased blood flow through the portal system in cirrhotic rats. Gastroenterology. 1984; 87(5):1120-6. View

Fallowfield J . Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011; 300(5):G709-15. DOI: 10.1152/ajpgi.00451.2010. View

Li Z, Zhang S, Lv G, Huang Y, Zhang W, Ren S . Changes in count and function of splenic lymphocytes from patients with portal hypertension. World J Gastroenterol. 2008; 14(15):2377-82. PMC: 2705093. DOI: 10.3748/wjg.14.2377. View

10.

Fiorucci S, Antonelli E, Mencarelli A, Orlandi S, Renga B, Rizzo G . The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology. 2005; 42(3):539-48. DOI: 10.1002/hep.20817. View

11.

Gemelli M, Manganaro R, Mami C, Buemi M, Paolata A, Marrone T . Endothelin-1 concentrations in cord blood of neonates with meconium-stained amniotic fluid. J Perinat Med. 2005; 33(3):259-61. DOI: 10.1515/JPM.2005.048. View

12.

Snowdon V, Guha N, Fallowfield J . Noninvasive evaluation of portal hypertension: emerging tools and techniques. Int J Hepatol. 2012; 2012:691089. PMC: 3376538. DOI: 10.1155/2012/691089. View

13.

Zhu Q, Zou L, Jagavelu K, Simonetto D, Huebert R, Jiang Z . Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol. 2011; 56(4):893-9. PMC: 3307873. DOI: 10.1016/j.jhep.2011.11.013. View

14.

Buck M, Garcia-Tsao G, Groszmann R, Stalling C, Grace N, Burroughs A . Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology. 2013; 59(3):1052-9. DOI: 10.1002/hep.26755. View

15.

Malamut G, Ziol M, Suarez F, Beaugrand M, Viallard J, Lascaux A . Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2007; 48(1):74-82. DOI: 10.1016/j.jhep.2007.08.011. View

16.

Coll M, Martell M, Raurell I, Ezkurdia N, Cuenca S, Hernandez-Losa J . Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver Int. 2009; 30(4):593-602. DOI: 10.1111/j.1478-3231.2009.02176.x. View

17.

Guo Y, Wu C, Liao Y, Zhang Q . The expression and significance of CD4+CD25+CD127low/- regulatory T cells and Foxp3 in patients with portal hypertension and hypersplenism. Hepatogastroenterology. 2013; 60(123):581-4. DOI: 10.5754/hge11381. View

18.

Meyer D, Bachem M, Gressner A . Modulation of hepatic lipocyte proteoglycan synthesis and proliferation by Kupffer cell-derived transforming growth factors type beta 1 and type alpha. Biochem Biophys Res Commun. 1990; 171(3):1122-9. DOI: 10.1016/0006-291x(90)90801-s. View

19.

Saito K, Nakanuma Y, Takegoshi K, Ohta G, Obata Y, Okuda K . Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire. Hepatogastroenterology. 1993; 40(2):163-6. View

20.

Mami C, Manganaro R, Marseglia L, Saitta G, Gemelli M, Martino F . Plasma leptin, insulin, and neuropeptide Y response to feeding in newborn infants. Arch Dis Child Fetal Neonatal Ed. 2006; 91(5):F389. PMC: 2672853. DOI: 10.1136/adc.2005.088716. View